Human umbilical cord mesenchymal stem cells via intramuscular injection influence the expression of cytokines related to dilated cardiomyopathy in rats

doi:10.3969/j.issn.2095-4344.2015.14.009

Abstract

Abstract:

BACKGROUND: Studies have shown that intramuscular transplantation of xenogeneic umbilical cord mesenchymal stem cells in a certain dose range is safe and reliable, and it also confirm that this approach is

equally safe and effective for heart failure in rats with dilated cardiomyopathy.

OBJECTIVE: To explore the effect of human umbilical cord mesenchymal stem cells through intramuscular injection on the cytokine expression in adriamycin-induced dilated cardiomyopathy (DCM) rats.

METHODS: Totally 160 rats were randomly divided into control group (n=20) and DCM group (n=140). Rats in the DCM group were administered adriamycin intraperitoneally to establish DCM model. The DCM rats were randomly subdivided into model control group (served as model group), cell supernatant group, the low-dose mesenchymal stem cell group (served as low-dose group), the middle-dose mesenchymal stem cell group (served as middle-dose group), and the high-dose mesenchymal stem cells group (served as high-dose group). Secondary injection was performed at 4 weeks after first injection.

RESULTS AND CONCLUSION: The ELISA test showed that the serum levels of vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), leukemia inhibitor factor (LIF) and granulocyte macrophage colony stimulating factor (GM-CSF) were higher in the model group than the control group before and after intramuscular injection (P < 0.05). After intramuscular injection, the levels of HGF, LIF, GM-CSF and VEGF in the low-dose group were increased significantly (P < 0.05), which were significantly higher than those in the model group (P < 0.05). The level of LIF in the middle-dose group was significantly elevated after injection (P < 0.05), while there were no significant differences in HGF, VEGF and GM-CSF levels in the high-dose group before and after intramuscular injection (P > 0.05). Both the immunohistochemical and RT-PCR results showed that the expressions of insulin-like growth factor-1, VEGF and HGF were increased in all the DCM rats as compared with the control group, which were increased most in the middle-dose group. These findings indicate that low-dose and middle-dose human umbilical cord mesenchymal stem cells intramuscular injection can increase the serum levels of HGF, LIF, GM-CSF, VEGF and the expressions of IGF-1, HGF and VEGF in the myocardium of DCM rats.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: Umbilical Cord, Mesenchymal Stem Cell Transplantation, Injections, Intramuscular, Cardiomyopathy, Dilated

CLC Number:

R394.2

Jiang Yan-jie, Mao Cheng-gang, Ning Xian-feng, Li Rong, Li Zi-pu. Human umbilical cord mesenchymal stem cells via intramuscular injection influence the expression of cytokines related to dilated cardiomyopathy in rats [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(14): 2179-2185.

Figures/Tables 3

References

[1] Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450-1456.
[2] Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355 (9215):1582-1587.
[3] Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004; 110(15):2180-2183.
[4] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13.
[5] Dandel M, Weng Y, Siniawski H, et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices.Circulation. 2005;112 (9 Suppl): I37-45.
[6] Sun CK, Chang LT, Sheu JJ, et al. Bone marrow-derived mononuclear cell therapy alleviates left ventricular remodeling and improves heart function in rat-dilated cardiomyopathy. Crit Care Med. 2009;37(4):1197-1205.
[7] 何红燕,林晓波,应文娟,等.人脐带间充质干细胞经体内定植并向心肌样细胞分化的研究[J].中国输血杂志,2009,22(3):188-191.
[8] 林晓波,何红燕,罗敏杰,等.人脐带间充质干细胞向心肌样细胞分化的研究[J].实用儿科临床杂志,2007, 22(13):971-973.
[9] Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther. 2006;14(6):840-850.
[10] 杨德忠,王伟,王薇,等.旁分泌机制在脂肪间充质干细胞移植治疗心肌梗死中的作用[J].第三军医大学学报,2013,35(9):874-879.
[11] Huang J, Zhang Z, Guo J, et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res. 2010;106(11):1753-1762.
[12] 张文祥,王思平,锡洪敏,等.Wistar 大鼠肌肉注射异种脐带间充质干细胞的安全性[J].中国组织工程研究, 2014, 18(41): 6620-6627.
[13] 王思平,聂娜娜,王丽,等.肌肉注射异种脐带间充质干细胞大鼠心肌肌钙蛋白 I 及血清相关因子的表达[J].中国组织工程研究, 2014, 18(10): 1566-1572.
[14] 王琪,张文祥,王思平,等. 肌肉注射人脐带间充质干细胞健康大鼠心肌组织ki-67, phh3及cTnT 的表达[J]. 中国组织工程研究, 2014, 18(41): 6671-6677.
[15] 王本臻. 肌肉注射人脐带间充质干细胞对阿霉素诱导扩张型心肌病大鼠心功能及心肌超微结构的影响[D]. 青岛:青岛大学, 2014.
[16] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
[17] Gnecchi M, Danieli P, Cervio E. Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol. 2012;57(1):48-55.
[18] van den Akker F, Deddens JC, Doevendans PA, et al. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta. 2013;1830(2):2449-2458.
[19] Mohammadi Gorji S, Karimpor Malekshah AA, Hashemi-Soteh MB, et al. Effect of mesenchymal stem cells on Doxorubicin-induced fibrosis. Cell J. 2012;14(2):142-151.
[20] Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells. 2007;25(2):319-331.
[21] Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349.
[22] Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-98.
[23] Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J. 2006;20(6):661-669.
[24] Tang YL, Zhao Q, Qin X, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80(1):229-236.
[25] Tögel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 2005;289(1):F31-42.
[26] Breitbach M, Bostani T, Roell W, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007; 110(4):1362-1369.
[27] Vulliet PR, Greeley M, Halloran SM, et al. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet. 2004;363(9411):783-784.
[28] Widimsky P, Penicka M. Complications after intracoronary stem cell transplantation in idiopathic dilated cardiomyopathy. Int J Cardiol. 2006;111(1):178-179.
[29] Yoon YS, Park JS, Tkebuchava T, et al. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 2004;109(25): 3154-3157.
[30] Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863-868.
[31] Menasché P, Hagège AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol. 2003;41(7): 1078-1083.
[32] Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410(6829): 701-705.
[33] Lin H, Shabbir A, Molnar M, et al. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells .J Cell Physiol. 2008;216(2):458-468.
[34] Vacanti V, Kong E, Suzuki G, et al. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol. 2005;205(2):194-201.
[35] Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest. 2005; 115(2):326-338.
[36] Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy.Circulation. 2005 ;112(8): 1128-1135.